Figure 4 | Scientific Reports

Figure 4

From: Impaired iloprost-induced platelet inhibition and phosphoproteome changes in patients with confirmed pseudohypoparathyroidism type Ia, linked to genetic mutations in GNAS

Figure 4

Iloprost-induced and PKA-mediated changes in phosphoproteome of control platelets. (A) Heatmap of 453 phosphopeptides assigned as upregulated (blue) or downregulated (orange) by 10 or 2 nM iloprost in control platelets (C1–4). Left lanes: mean effects in platelets from the control subjects (C’). Phosphopeptides were ordered according to mean effect size by 10 nM iloprost. Next lanes: iloprost effects for the control subjects. Relevant regulated changes were arbitrarily thresholded for outside range of log2 − 0.322 to + 0.322. (B) Numbers of phosphopeptides identified as up- or downregulated by iloprost in ≥ 3 control subjects. (C) Fractions of phosphopeptides identified as up- or downregulated with a PKA consensus site; percentages refer to overlap with previous identification19. (D) Venn diagrams presenting relevant up- and downregulated proteins by 2 or 10 nM iloprost. Left circles: previously identified, right circles: positive PKA consensus site.

Back to article page